{"id":"https://openalex.org/W4237222949","doi":"https://doi.org/10.2174/1381612811306040734","title":"New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors","display_name":"New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors","publication_year":2012,"publication_date":"2012-12-01","ids":{"openalex":"https://openalex.org/W4237222949","doi":"https://doi.org/10.2174/1381612811306040734","mag":"2113912758","pmid":"https://pubmed.ncbi.nlm.nih.gov/23016853","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4171085"},"language":"en","primary_location":{"id":"doi:10.2174/1381612811306040734","doi":"https://doi.org/10.2174/1381612811306040734","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1381612811306040734","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4171085","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018088896","display_name":"Michele Cea","orcid":"https://orcid.org/0000-0002-1530-6729","observed_orcids":["https://orcid.org/0000-0002-1530-6729"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michele Cea","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062694802","display_name":"Antonia Cagnetta","orcid":"https://orcid.org/0000-0003-1973-3768","observed_orcids":["https://orcid.org/0000-0003-1973-3768"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Antonia Cagnetta","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078922292","display_name":"Marco Gobbi","orcid":"https://orcid.org/0000-0003-0756-109X","observed_orcids":["https://orcid.org/0000-0003-0756-109X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marco Gobbi","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060112940","display_name":"Franco Patrone","orcid":"https://orcid.org/0000-0003-4170-9131","observed_orcids":["https://orcid.org/0000-0003-4170-9131"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Franco Patrone","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul G. Richardson","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091207345","display_name":"Teru Hideshima","orcid":"https://orcid.org/0000-0003-2939-6224","observed_orcids":["https://orcid.org/0000-0003-2939-6224"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Teru Hideshima","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":null,"apc_paid":null,"fwci":3.68,"has_fulltext":false,"cited_by_count":38,"citation_normalized_percentile":{"value":0.9381471,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"19","issue":"4","first_page":"734","last_page":"744"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9814000129699707,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9814000129699707,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.017799999564886093,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":1.0},{"id":"https://openalex.org/keywords/vorinostat","display_name":"vorinostat","score":0.9959999918937683},{"id":"https://openalex.org/keywords/panobinostat","display_name":"panobinostat","score":0.9779999852180481},{"id":"https://openalex.org/keywords/epigenetic-regulation","display_name":"epigenetic regulation","score":0.8349999785423279},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9340000152587891},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.9089999794960022},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.7480000257492065},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8889999985694885},{"id":"https://openalex.org/keywords/plasma-cell-malignancy","display_name":"plasma cell malignancy","score":0.6510000228881836}],"concepts":[{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.9105391502380371},{"id":"https://openalex.org/C2776262904","wikidata":"https://www.wikidata.org/wiki/Q905901","display_name":"Vorinostat","level":5,"score":0.8467316031455994},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7867608070373535},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.686000406742096},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.6239362359046936},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.616959273815155},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5919587016105652},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.5796606540679932},{"id":"https://openalex.org/C41091548","wikidata":"https://www.wikidata.org/wiki/Q26939","display_name":"Epigenetics","level":3,"score":0.5212436318397522},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4681470990180969},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.44976669549942017},{"id":"https://openalex.org/C121912465","wikidata":"https://www.wikidata.org/wiki/Q3589153","display_name":"Epigenomics","level":5,"score":0.4447823762893677},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.41806870698928833},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3900882303714752},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38929733633995056},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.34007519483566284},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22853711247444153},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.2073960304260254},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.12370720505714417},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.12344962358474731},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.10356208682060242},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08531409502029419},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08052366971969604}],"mesh":[{"descriptor_ui":"D000077337","descriptor_name":"Vorinostat","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077767","descriptor_name":"Panobinostat","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006877","descriptor_name":"Hydroxamic Acids","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006877","descriptor_name":"Hydroxamic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044127","descriptor_name":"Epigenesis, Genetic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059016","descriptor_name":"Tumor Microenvironment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.2174/1381612811306040734","doi":"https://doi.org/10.2174/1381612811306040734","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1381612811306040734","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},{"id":"doi:10.2174/13816128130412","doi":"https://doi.org/10.2174/13816128130412","is_oa":false,"landing_page_url":"https://doi.org/10.2174/13816128130412","pdf_url":null,"source":{"id":"https://openalex.org/S55674637","display_name":"Current Pharmaceutical Design","issn_l":"1381-6128","issn":["1381-6128","1873-4286"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Pharmaceutical Design","raw_type":"journal-article"},{"id":"pmid:23016853","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23016853","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current pharmaceutical design","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:3139756","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4171085","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4171085","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4171085","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Curr Pharm Des","raw_type":"Text"},{"id":"mag:2113912758","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23016853","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3139756","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4171085","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3549977710","display_name":"Host-tumor cell interaction in myeloma: therapeutic applications","funder_award_id":"5p01ca078378-15","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G4933731489","display_name":"SPORE in Multiple Myeloma","funder_award_id":"P50CA100707","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G5276536440","display_name":"Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications","funder_award_id":"R01CA050947","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000867162","display_name":"Integrative Oncogenomics of Multiple Myeloma","funder_award_id":"P01CA155258","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":2,"referenced_works":["https://openalex.org/W1552130853","https://openalex.org/W1899314386"],"related_works":["https://openalex.org/W2346514565","https://openalex.org/W2027652423","https://openalex.org/W4395037776","https://openalex.org/W2093255555","https://openalex.org/W2219889428","https://openalex.org/W2048439525","https://openalex.org/W2204090931","https://openalex.org/W4376641511","https://openalex.org/W1984518316","https://openalex.org/W2059812275"],"abstract_inverted_index":{"Multiple":[0],"Myeloma":[1],"(MM)":[2],"is":[3,89,105],"a":[4,28,57],"common":[5],"hematologic":[6],"malignancy":[7],"of":[8,15,31,60,68,79,152,165,172],"plasma":[9],"cells":[10,154],"representing":[11],"an":[12,44],"excellent":[13],"model":[14],"epigenomics":[16],"dysregulation":[17],"in":[18,24,65,86,115,118,175],"human":[19],"disease.":[20],"Importantly,":[21],"these":[22],"findings,":[23],"addition":[25],"to":[26,37,96,99,111,138],"providing":[27],"better":[29],"understanding":[30],"the":[32,41,77,83,150,168],"underlying":[33,134],"molecular":[34,132,160],"changes":[35],"leading":[36],"this":[38,87,135],"malignance,":[39],"furnish":[40],"basis":[42,133],"for":[43,76],"innovative":[45],"therapeutic":[46],"approach.":[47],"Histone":[48],"deacetylase":[49],"inhibitors":[50,128],"(HDACIs),":[51],"including":[52,129],"Vorinostat":[53],"and":[54,91,117,141,167,177],"Panobinostat,":[55],"represent":[56],"novel":[58],"class":[59],"drugs":[61],"targeting":[62],"enzymes":[63],"involved":[64],"epigenetic":[66],"regulation":[67],"gene":[69],"expression,":[70],"which":[71],"have":[72],"been":[73],"evaluated":[74],"also":[75],"treatment":[78],"multiple":[80],"myeloma.":[81],"Although":[82],"clinical":[84,173],"role":[85],"setting":[88],"evolving":[90],"their":[92],"precise":[93],"utility":[94],"remains":[95],"be":[97,112,139],"determined,":[98],"date":[100],"that":[101],"single-agent":[102],"anti-MM":[103,124],"activity":[104],"modest.":[106],"More":[107],"importantly,":[108],"HDACIs":[109,166],"appear":[110],"synergistic":[113],"both":[114],"vitro":[116],"vivo":[119],"when":[120],"combined":[121],"with":[122,144,155],"other":[123],"agents,":[125],"mainly":[126],"proteasome":[127],"bortezomib.":[130],"The":[131],"synergism":[136],"seems":[137],"multifactorial":[140],"involves":[142],"interference":[143],"protein":[145],"degradation":[146],"as":[147,149],"well":[148],"interaction":[151],"myeloma":[153],"microenvironment.":[156],"Here":[157],"we":[158],"review":[159],"events":[161],"underling":[162],"antitumor":[163],"effects":[164],"most":[169],"recent":[170],"results":[171],"trials":[174],"relapsed":[176],"refractory":[178],"MM.":[179]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2022-05-12T00:00:00"}